SCHEMBL6480944

SCHEMBL6480944

[C]c1cc(Oc2ccc(N)cc2OC)ccn1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 2/20 0.47
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
NR4A1 P22736 1/20 0.40
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KDR P35968 1/20 0.38
EGFR P00533 1/20 0.37
CYP19A1 P11511 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4795727 0.85 MAPT (0.47) GAAMAPTKDM4EPDGFRBPDGFRA
SCHEMBL4798025 0.81 MAPT (0.49) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL6388264 0.80 KDM4E (0.48) GAAMAPTKDM4EPDGFRBPDGFRA
SCHEMBL29764086 0.78 MAPT (0.56) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL23095 0.78 MAPT (0.56) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL4800435 0.77 MAPT (0.45) GAAMAPTKDM4EPDGFRBPDGFRA
SCHEMBL31457261 0.77 MAPT (0.55) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL310789 0.75 MAPT (0.58) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL29764004 0.75 MAPT (0.58) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL11401708 0.75 MAPK1 (0.56) GAAMAPTKDM4ETSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076488-B2 Antiproliferative agents; angiogenesis inhibitors; anticancer agents BAYER HEALTHCARE LLC (US) 2011-12-13 US disclosed
US-20050038031-A1 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders BAYER HEALTHCARE LLC 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038031-A1 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders CCNC, UACA, SLC14A1 GAA 3026/4885MAPT 1011/4885KDM4E 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.